Our BioChip is developed to tackle difficulties in distinguishing diseases with very similar symptoms and aid front-line professionals with making patient management decisions. This is achieved by targeting multiple diseases through a microarray.
Get Multiple Results Through Our Scalable Array-Based BioChip
Global episodes and deaths attributable to lower respiratory infections in 2016 are around 300 million. Respiratory infections place a significant socioeconomic burden on individuals, families, and society. It causes illnesses that range in severity and sometimes lead to hospitalization and death.
With our multiplex BioChip, we provide 5-in-1 respiratory diseases diagnostics for SARS-CoV-2, RSV, Streptococcus, Influenza A and Influenza B
Dengue fever is common in more than 100 countries around the world. 40% of the world’s population, about 3 billion people, live in areas with a risk of dengue. A blood test is the only way to confirm the diagnosis.
With our ALiA® platform, we provide a one-stop blood test for dengue and similar viruses like Zika or chikungunya within 15 minutes.
More than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. WHO estimated 376 million new infections with 1 of 4 STIs: chlamydia (127 million), gonorrhoea (87 million), syphilis (6.3 million), and trichomoniasis (156 million).
With ALiA® BioChip, a quick screen of suspected viral infections can be achieved at the point of care scenarios for men and women.
Rapid diagnostics of Sepsis play an important role in relieving the burden of over 10 million global cases of blood infection-related death.
Respiratory and diarrhea infections are the largest contributors to sepsis cases and sepsis-related mortality across all ages in 2017.
With our development of Sepsis panel, we offer a comprehensive diagnostic solution for life-threatening and time-critical infections.
Outbreak of gastrointestinal infections (GI) is a serious concern in hospitals. Clostridium difficile infection (CDI) is a major cause of hospital-associated GI illness and creates a huge burden on the healthcare system. With our array-based BioChip, we provide diagnostic tests for CDI and its toxins, which can be further developed into panels distinguishing viral, bacterial, and parasite infections.
The ALiA® SARS-CoV-2 Antigen FIA Test employs a unique immunofluorescent-based BioChip with our advanced microfluidic and microarray technologies for the qualitative detection of nucleocapsid protein from SARS-CoV-2.
The ALiA® SARS-CoV-2 Antigen FIA Test delivers a 20-minute result of direct nasopharyngeal swab from COVID-19 suspected patients with symptoms onset within 14 days.
Benefiting from our well-established Lab-On-Chip (LOC) platform (including the POC device and the Lab-On-Chip BioChip), the multiplexing microarray development for various test panels (e.g. 5-in-1 respiratory virus panel) is scalable with a short period of 6-9 months for new application adaption.